Beta-2-Microglobulin in Autism Spectrum Disorders
Paula Goines, Joseph Schauer, Luke Heuer, Paul Ashwood and Judy Van De Water
DOI : 10.3844/ajbbsp.2007.87.91
American Journal of Biochemistry and Biotechnology
Volume 3, Issue 2
Autism spectrum disorders (ASD) are heterogeneous neurodevelopmental diseases of unknown etiology. There are no biological markers for ASD and current diagnosis is based on behavioral criteria. Recent data has shown that MHC I, a compound involved in adaptive immune function, is also involved in neurodevelopment, synaptic plasticity and behavior. It has been suggested that altered MHC I expression could play a part in neurodevelopmental diseases like ASD. To address this possibility, we measured plasma levels of beta-2-microglobulin (Î²2m), a molecule that associates with MHC I and is indicative of MHC I expression, in 36 children with autism, 28 typically developing controls and subjects with developmental disabilities (n=16) but not autism. The age range of our study population was 17-120 months. We found no statistically significant differences in plasma β2m levels between groups. Therefore, plasma levels of Î²2m measured in early childhood in autism may not reflect changes in MHC class I in autism.
© 2007 Paula Goines, Joseph Schauer, Luke Heuer, Paul Ashwood and Judy Van De Water. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.